OLDWICK, N.J., April 2, 2019 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical
company dedicated to intercepting and preventing immune-mediated
diseases, today announced the appointment of Douglas Jacobstein, M.D., as Vice President of
Clinical Development, and Alex
Rabiee as Vice President of Business Development.
![(PRNewsfoto/Provention Bio, Inc.) (PRNewsfoto/Provention Bio, Inc.)](https://mma.prnewswire.com/media/720849/Provention_Bio_Logo.jpg)
"The addition of Doug and Alex further strengthens our
leadership team as we advance the clinical development of our
pioneering portfolio of immune-mediated interception and prevention
assets," stated Ashleigh Palmer, CEO
of Provention Bio. "Doug's gastroenterology expertise and extensive
clinical development experience will be invaluable as we advance
our inflammatory bowel disease assets and prepare for next year's
start of our Phase 2b PROACTIVE study
of PRV-015 (anti-IL-15) in gluten free diet non-responsive celiac
patients. Alex has a proven track record in designing,
executing and leveraging long-term value-creating partnerships,
which will be essential as our pipeline progresses towards more
advanced stages of clinical development and potential
commercialization. We welcome Doug and Alex to the team and
look forward to their contributions as we work to transform the
therapeutic landscape for immune-mediated diseases."
Dr. Jacobstein brings to Provention almost 15 years of clinical
development, management and leadership expertise. He most recently
served as Director of Clinical Development in the Immunology
division of Janssen Pharmaceuticals, where he helped develop study
designs and protocols for clinical programs. Previously, he was
Director of Clinical Affairs, Autoimmunity, in the
ImmunoDiagnostics Division of Thermo Fisher Scientific. Prior to
joining Thermo Fisher, Dr.
Jacobstein was Senior Director of Medical Affairs at Osiris
Therapeutics and held various positions in medical affairs and
clinical development at UCB and Alba Therapeutics. Dr. Jacobstein
practiced as an Attending Physician at The Sinai Hospital of
Baltimore following completion of
his fellowship in pediatric gastroenterology at the Children's
Hospital of Philadelphia. He
received his medical degree from the University of Maryland School of Medicine and holds
a BS from Cornell University.
Mr. Rabiee brings 15 years of experience in the biotechnology
sector, most recently serving as Director of Business Development
at Amgen. He joined Amgen in 2004 and held positions of increasing
responsibility including R&D program management and business
development. Alex acted as a transaction lead on numerous completed
out-license and collaboration transactions. Mr. Rabiee holds an MBA
from UCLA Anderson School of Management and a BS in Biology from UC
Irvine.
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy that is
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to in-license, transform and
develop therapeutic candidates targeting the high morbidity,
mortality and escalating costs of autoimmune and inflammatory
diseases including: type 1 diabetes (T1D), Crohn's disease,
ulcerative colitis, celiac disease, lupus, and certain
life-threatening viral diseases. Provention's diversified portfolio
includes advanced-stage product development candidates that have
undergone clinical testing by other companies. For more information
on Provention Bio, please visit www.proventionbio.com.
Forward Looking Statements
Certain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, risks related to failure to obtain FDA approvals or
clearances and noncompliance with FDA regulations; uncertainties of
patent protection and litigation; limited research and development
efforts and dependence upon third parties; substantial competition;
our need for additional financing and the risks listed under "Risk
factors" in our annual report on Form 10-K for the year ended
December 31, 2018 and any subsequent
filings with the Securities and Exchange Commission (SEC). As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Provention does not undertake an obligation to update
or revise any forward-looking statement. The information set forth
herein speaks only as of the date hereof.
Investors:
Kimberly
Minarovich or Sam Martin,
Argot Partners
Kimberly@argotpartners.com or Sam@argotpartners.com
212-600-1902
Media:
David Rosen,
Argot Partners
David.Rosen@argotpartners.com
212-600-1902
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-key-additions-to-its-senior-management-team-300822385.html
SOURCE Provention Bio, Inc.